Allogeneic MSC Therapy
Acute liver failure, cirrhosis, multiple sclerosis, lupus, type 1 diabetes
Pre-clinicalActive
Key Facts
Indication
Acute liver failure, cirrhosis, multiple sclerosis, lupus, type 1 diabetes
Phase
Pre-clinical
Status
Active
Company
About Oxacell
Oxacell AG is a private, clinical-stage biotech based in Potsdam/Munich, Germany, specializing in advanced therapy medicinal products (ATMPs) using adipose-derived mesenchymal stem cells. The company operates a GMP-certified manufacturing platform and is developing both autologous and allogeneic cell therapies targeting orthopedic, autoimmune, and liver diseases. While likely pre-revenue from product sales, its strategy involves certified collection centers, academic partnerships, and a pipeline progressing through clinical development and regulatory pathways.
View full company profile